1. A lower dosage of imatinib is sufficient to maintain undetectable disease in patients with chronic myeloid leukemia with long-term low-grade toxicity of the treatment. Issue 2 (1st February 2016) Authors: Faber, Edgar; Divoká, Martina; Skoumalová, Ivana; Novák, Martin; Marešová, Ivana; Mičová, Kateřina; Friedecký, David; Adam, Tomáš; Jarošová, Marie; Indrák, Karel Journal: Leukemia & lymphoma Issue: Volume 57:Issue 2(2016:Feb.) Page Start: 370 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗